Ro's Obesity Strategy Targets Payers
Ro
Obesity pushes Ro out of the one click convenience business and into chronic care infrastructure. Erectile dysfunction and hair loss were mostly cash pay, episodic purchases. Obesity care is different, because roughly 40.3% of U.S. adults have obesity, treatment often lasts for years, and the workflow includes labs, dose changes, side effect monitoring, and insurance approval work, which lets Ro charge ongoing care fees and participate in much larger healthcare budgets.
-
Ro built Ro Body as a monthly program, not a one time visit. The service bundles 24/7 telehealth access with obesity management, and Ro added home phlebotomy, diagnostics, a lab, and owned pharmacies so it can collect tests, adjust medication, and ship treatment through one system.
-
The buyer changes from an individual paying for privacy and speed to insurers, employers, and drug makers paying for managed access. Ro now runs insurance checks and prior authorization support, and its Amgen collaboration focuses on real world barriers like coverage rules and payer criteria.
-
This also changes who Ro competes with. In obesity, Ro is no longer just next to Hims or other D2C telehealth apps. It is also up against weight focused programs like Noom and employer benefits vendors like Virta, which sell ongoing outcomes management into plans and self insured employers.
The next step is for Ro to turn obesity from a consumer acquisition engine into a payer facing platform. If it can prove adherence, weight loss, and lower total drug spend, it moves closer to the core healthcare budget, where contracts are larger, relationships last longer, and obesity becomes the wedge for a broader chronic disease business.